Health Economics and Outcomes Research in Global Healthcare

By Staff Writer

February 26, 2024

Introduction:

Health Economics and Outcomes Research (HEOR) has emerged as a critical tool in shaping healthcare decisions globally. In addition to the growing complexity of healthcare, the numerous challenges that are currently being faced in the healthcare industry, such as the growing number of innovative curative therapies that come at a high cost, the movement toward universal healthcare in several countries especially in low- and middle income countries (LMICs), and the requirement to provide optimal health outcomes for patients while adhering to budgetary constraints, are bringing the demand for HEOR further into the spotlight.

The ISPOR Science Strategy:

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) has developed a Science Strategy to identify key themes that can impact HEOR and global healthcare. This strategy aligns with ISPOR’s mission to promote HEOR excellence to improve global health decision-making. It also ties in with ISPOR’s Strategic Plan Update 2024, which prioritises good research practices, dialogue platforms, and education related to new and emerging healthcare trends.

Economic Evaluation Methods:

Economic evaluation, including cost-effectiveness and cost-benefit analysis, can guide healthcare decision-making by comparing costs and outcomes. Furthermore, it requires measuring the societal readiness to pay. Health economic evaluation methods are well-established but may not reflect all considerations in real-world decision making. Key areas for further research include improving economic analysis to capture broader elements of value beyond the quality-adjusted life-year (QALY), addressing complex clinical pathways, and advancing methods for open research.

HTA in Healthcare Decision Making:

Health Technology Assessment (HTA) is a multidisciplinary approach that evaluates the value of health technologies throughout their lifecycle using specified techniques. The goal is to achieve an egalitarian, efficient, and high-quality health system through informed decision-making. In countries with universal healthcare, HTA examinations tend to be more systematic and organised. Strengthening the connection between HTA and decision-making can improve the efficiency, transparency, and fairness of this process. HEOR can help strengthen these linkages by developing methods that influence universal health coverage and health system design.

HEOR in Low and Middle-Income Countries:

As more countries move towards universal healthcare, prioritisation within limited budgets becomes paramount. Distinct healthcare needs in LMICs lead to distinct HEOR target points compared to developed countries. As more LMICs adopt universal healthcare systems, prioritising healthcare services becomes crucial and additional aspects including communicable diseases become fundamental in these countries. HEOR methods can be adapted to facilitate and align priority-setting across all aspects of a health delivery system. However, these methods are only helpful if there is synergy across problem definition, evidence generation, and decision-making.

Conclusion:

HEOR is playing an increasingly important role in shaping the future of healthcare. By providing a framework for informed decision-making, HEOR has the potential to improve patient outcomes and societal well-being. As healthcare continues to evolve, the importance of HEOR will only increase.

Reference url

Recent Posts

access to medicines
         

Quantifying EU Medicine Access Challenges

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.